BRPI0513129A - método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo - Google Patents

método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo

Info

Publication number
BRPI0513129A
BRPI0513129A BRPI0513129-4A BRPI0513129A BRPI0513129A BR PI0513129 A BRPI0513129 A BR PI0513129A BR PI0513129 A BRPI0513129 A BR PI0513129A BR PI0513129 A BRPI0513129 A BR PI0513129A
Authority
BR
Brazil
Prior art keywords
hypogonadism
group
condition selected
treating
prostate cancer
Prior art date
Application number
BRPI0513129-4A
Other languages
English (en)
Inventor
Joseph Podolski
Ronald Wiehle
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of BRPI0513129A publication Critical patent/BRPI0513129A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Método de Tratamento de Condição Selecionada do Grupo que Consiste em Hipertrofia Benigna da Próstata, Câncer de Próstata, Trigliceridos Elevados, Colesterol Alto e Hipogonadismo Podem ser usadas composições que compreendem transclomifeno no tratamento da hipertrofia benigna da próstata, câncer de próstata, níveis elevados de trigliceridos e hipogonadismo.
BRPI0513129-4A 2004-07-14 2005-07-14 método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo BRPI0513129A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58822304P 2004-07-14 2004-07-14
US58813004P 2004-07-14 2004-07-14
US58812304P 2004-07-14 2004-07-14
PCT/US2005/025000 WO2006019916A1 (en) 2004-07-14 2005-07-14 Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol

Publications (1)

Publication Number Publication Date
BRPI0513129A true BRPI0513129A (pt) 2008-04-29

Family

ID=35134086

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513129-4A BRPI0513129A (pt) 2004-07-14 2005-07-14 método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo

Country Status (6)

Country Link
US (1) US20080242726A1 (pt)
EP (1) EP1776098A1 (pt)
BR (1) BRPI0513129A (pt)
EC (1) ECSP077247A (pt)
MX (1) MX2007000050A (pt)
WO (1) WO2006019916A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1289075C (zh) 2001-07-09 2006-12-13 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物的用途
US7737185B2 (en) 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
NZ560551A (en) * 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
MX2010004195A (es) * 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
SG10201704820SA (en) 2012-08-21 2017-07-28 Repros Therapeutics Inc Trans-clomiphene formulations and uses thereof
CN104994877A (zh) * 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬
US20160051495A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America Oral Transmucosal Compositions including C-SERMs for Low Testosterone Levels in Men
JP2019506425A (ja) * 2016-02-25 2019-03-07 アスペン パーク ファーマシューティカルズ，インコーポレイティド クロミフェン異性体の経口剤形および続発性性腺機能低下症を治療するために経口剤形を使用する方法
CN108420806A (zh) * 2017-02-15 2018-08-21 武汉华杰世纪生物医药有限公司 具有靶向性的抗肿瘤药物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061733A (en) * 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
CA2228610C (en) * 1995-08-17 2008-06-03 Heidi Rolfes Controlled release products
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
ATE277739T1 (de) * 1996-10-28 2004-10-15 Gen Mills Inc Einbettung und einkapselung von teilchen zur kontrollierten abgabe
JP4496316B2 (ja) * 1997-04-03 2010-07-07 エーザイ インコーポレイテッド 生分解性テレフタレートポリエステル−ポリホスフェートポリマー、組成物、物品、並びにその製造及び使用方法
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
DE69935335T2 (de) * 1998-08-07 2007-11-22 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazole als modulatoren des östrogenrezeptors
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP5184727B2 (ja) * 1999-06-11 2013-04-17 ワトソン ファーマシューティカルズ， インコーポレイテッド 女性への非経口アンドロゲンステロイドの投与
CA2321321A1 (en) * 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US20020004065A1 (en) * 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
WO2001091744A1 (en) * 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
AU7850401A (en) * 2000-07-22 2002-02-05 Hubertus Greschbach Module for building platforms
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6743448B2 (en) * 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
CN1289075C (zh) * 2001-07-09 2006-12-13 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物的用途
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) * 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators

Also Published As

Publication number Publication date
ECSP077247A (es) 2007-03-29
WO2006019916A1 (en) 2006-02-23
EP1776098A1 (en) 2007-04-25
US20080242726A1 (en) 2008-10-02
MX2007000050A (es) 2007-07-10

Similar Documents

Publication Publication Date Title
ECSP077247A (es) Trans - clomifeno para el tratamiento de la hipertrofia prostatica benigna, cancer prostatico, hipogonodismo, trigliceridos elevados y alto colesterol
PT1318837E (pt) Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
MX2007003093A (es) Composiciones de tratamientos de lavanderia.
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
MXPA03003151A (es) Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata.
WO2006130429A3 (en) Treatment of cancer
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2011004260A3 (en) Composition for the treatment of benign prostate hyperplasia
WO2002030465A3 (en) Compositions that inhibit proliferation of cancer cells
GB2440871A (en) Methods and compositions for delaying the release of treatment chemicals
WO2008063760A3 (en) Methods for treating cancer targeting transglutaminase
WO2005096704A3 (en) Cholesterol lowering composition
MX2008002057A (es) Complejo de inclusion del inhibidor del factor xa con ciclodextrina.
WO2003024405A3 (en) Methods and compositions for inhibiting the proliferation of prostate cancer cells
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2008115478A3 (en) Method of cancer detection and treatment
WO2004069148A3 (en) Snornai-small nucleolar rna degradation by rna interference in trypanosomatids
MXPA05011213A (es) Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia.
WO2006089681A3 (de) Verfahren zur erhöhung der laserzerstörschwelle von beugungsgittern
MXPA05012780A (es) Metodo para tratar estructuras fibrosas.
WO2010019772A3 (en) Oxadiazole-2-oxides as antischistosomal agents
WO2007126787A3 (en) Reagents and methods for cancer treatment and prevention
WO2008033887A8 (en) Methods for treating cancer
DK1623740T3 (da) Farmaceutisk sammensætning og metode til behandling af og forebyggelse mod prostatahyperplasi og prostatitis under anvendelse af frugter og Roystonea regis (kongepalme)
EP1584736A3 (en) Method for bleaching fibrous articles

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 020130047159/RJ DE 29.05.2013, EM VIRTUDE DO DISPOSTO NO ARTIGO 219 INCISO II DA LPI NO 9.279/96, UMA VEZ QUE NAO HA FUNDAMENTACAO LEGAL.

B151 Others concerning applications: resolution cancelled

Free format text: ANULADO O DESPACHO 15.7 DA RPI 2224 DE 20/08/2013, POR TER SIDO INDEVIDO.